Figure 3.
Figure 3. Event-free survival after high-risk ALL with or without DS, by treatment era. (A) Event-free survival in a cohort of 3320 children treated for ALL on CCG therapeutic protocols between 1983 and 1995 with high-risk features: a comparison by presence (ALL-DS) or absence (ALL-NDS) of Down syndrome. (B) Event-free survival in a cohort of 1426 children treated for ALL on CCG therapeutic protocols between 1983 and 1989 (Early Era) with high-risk features: a comparison by presence (ALL-DS) or absence (ALL-NDS) of Down syndrome. (C) Event-free survival in a cohort of 1894 children treated for ALL on CCG therapeutic protocols between 1989 and 1995 (Recent Era) with high-risk features: a comparison by presence (ALL-DS) or absence (ALL-NDS) of Down syndrome.

Event-free survival after high-risk ALL with or without DS, by treatment era. (A) Event-free survival in a cohort of 3320 children treated for ALL on CCG therapeutic protocols between 1983 and 1995 with high-risk features: a comparison by presence (ALL-DS) or absence (ALL-NDS) of Down syndrome. (B) Event-free survival in a cohort of 1426 children treated for ALL on CCG therapeutic protocols between 1983 and 1989 (Early Era) with high-risk features: a comparison by presence (ALL-DS) or absence (ALL-NDS) of Down syndrome. (C) Event-free survival in a cohort of 1894 children treated for ALL on CCG therapeutic protocols between 1989 and 1995 (Recent Era) with high-risk features: a comparison by presence (ALL-DS) or absence (ALL-NDS) of Down syndrome.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal